LIQUIDIA CORPORATION Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
LIQUIDIA CORPORATION (LQDA) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $12.86 per share for the 12-month period ending 2024-12-31, per its 8-K filed 2025-05-08.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2025-05-08
- LIQUIDIA CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2024-03-31 was $12.86, a 108.43% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2023-03-31 was $6.17, a 13.00% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2022-03-31 was $5.46, a 95.00% increase year-over-year.
- LIQUIDIA CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $2.80.
- LIQUIDIA CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $6.57, a 25.86% increase from fiscal 2022.
- LIQUIDIA CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $5.22, a 91.91% increase from fiscal 2021.
- LIQUIDIA CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2021 was $2.72, a 27.47% decline from fiscal 2020.
- LIQUIDIA CORPORATION share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2020 was $3.75.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $12.86 8-K · filed 2025-05-08 | |||
| 2024-09-30 | $12.86 10-Q · filed 2024-11-13 | |||
| 2024-06-30 | $12.86 10-Q · filed 2024-08-07 | |||
| 2024-03-31 | $12.86 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $6.57 10-K · filed 2024-03-13 | |||
| 2023-09-30 | $6.57 10-Q · filed 2023-11-07 | |||
| 2023-06-30 | $6.56 10-Q · filed 2023-08-10 | |||
| 2023-03-31 | $6.17 10-Q · filed 2023-05-08 | |||
| 2022-12-31 | $5.22 10-K · filed 2023-03-20 | |||
| 2022-09-30 | $5.22 10-Q · filed 2022-11-08 | |||
| 2022-06-30 | $5.29 10-Q · filed 2022-08-11 | |||
| 2022-03-31 | $5.46 10-Q · filed 2022-05-12 | |||
| 2021-12-31 | $2.72 10-K · filed 2022-03-17 | |||
| 2021-09-30 | $2.70 10-Q · filed 2021-11-03 | |||
| 2021-06-30 | $2.78 10-Q · filed 2021-08-10 | |||
| 2021-03-31 | $2.80 10-Q · filed 2021-05-13 | |||
| 2020-12-31 | $3.75 10-K · filed 2021-03-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Amneal Pharmaceuticals, Inc. (AMRX) | $6.326B | 25.62 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| Mirum Pharmaceuticals, Inc. (MIRM) | United States | $5.798B | -8.81 |
| Travere Therapeutics, Inc. (TVTX) | United States | $5.712B | -123.10 |
| Oruka Therapeutics, Inc. (ORKA) | United States | $5.663B | -43.76 |
| Cogent Biosciences, Inc. (COGT) | United States | $5.450B | -17.61 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Gossamer Bio, Inc. (GOSS) | United States | $5.355B | -0.65 |
| PTC THERAPEUTICS, INC. (PTCT) | United States | $5.199B | -177.07 |